Literature DB >> 11018

Analgesia produced by morphine when acting from the liquor space.

P K Dey, W Feldberg.   

Abstract

1 In cats analgesia was produced by morphine sulphate introduced into different parts of the liquor space in doses too small to be effective on intravenous injection. Analgesia was measured with the tail pinch method of Russell & Tate (1975). 2 On infusion into the fourth ventricle or into the subarachnoid space beneath the ventral surface of the brain stem caudal to the pons, doses of 100 to 200 mug of morphine sulphate were sufficient to produce strong long-lasting analgesia. On injection into the cisterna magna somewhat larger doses (400 to 800mug) were required. 3 It is concluded that the site where morphine acts when producing analgesia in all three circumstances is at the ventral surface of the brain stem. 4 The possibility is discussed that the structures acted upon are tryptaminergic nerve fibres. They arise from the raphe nuclei, belong to a descending inhibitory pathway, and on their way to the spinal cord, reach the ventral surface of the brain stem lateral to each pyramid, where they could be reached and acted upon by the morphine. This theory postulates a morphine sensitivity of tryptaminergic nerve fibres.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11018      PMCID: PMC1667605          DOI: 10.1111/j.1476-5381.1976.tb07715.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Morphine analgesia: blockade by raphe magnus lesions.

Authors:  H K Proudfit; E G Anderson
Journal:  Brain Res       Date:  1975-11-21       Impact factor: 3.252

2.  Hyperglycaemia produced by drugs with analgesic properties introduced into the cerebral ventricles of cats.

Authors:  P K Dey; W Feldberg
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

3.  Enhancement by morphine of the central descending inhibitory influence on spinal sensory transmission.

Authors:  M Sato; H Takagi
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

4.  Modification of morphine analgesia by drugs affecting adrenergic and tryptaminergic mechanisms.

Authors:  M R Fennessy; J R Lee
Journal:  J Pharm Pharmacol       Date:  1970-12       Impact factor: 3.765

5.  Effects of 5,6-dihydroxytryptamine on monoaminergic neurones in the central nervous system of the rat.

Authors:  H G Baumgarten; K D Evetts; R B Holman; L L Iversen; M Vogt; G Wilson
Journal:  J Neurochem       Date:  1972-06       Impact factor: 5.372

6.  Central monoamines and antinociceptive drug action.

Authors:  B D Görlitz; H H Frey
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

7.  Antagonism of stimulation-produced analgesia by p-CPA, a serotonin synthesis inhibitor.

Authors:  H Akil; D J Mayer
Journal:  Brain Res       Date:  1972-09-29       Impact factor: 3.252

8.  [Analgesia induced by stimulation of the cat central nucleus of the raphe].

Authors:  F Redjemi; M J Oliveras; G Guilbaud; J M Besson
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1974-09-23

9.  The effect of lowering the 5-hydroxytryptamine content of the rat spinal cord on analgesia produced by morphine.

Authors:  M Vogt
Journal:  J Physiol       Date:  1974-01       Impact factor: 5.182

10.  Monoaminergic mechanisms of stimulation-produced analgesia.

Authors:  H Akil; J C Liebeskind
Journal:  Brain Res       Date:  1975-08-29       Impact factor: 3.252

View more
  3 in total

1.  Proceedings of the British Pharmacological Society. Leeds, 12th-14th July 1989. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

2.  C-fragment of lipotropin--an endogenous potent analgesic peptide.

Authors:  W Feldberg; D G Smyth
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

3.  Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation.

Authors:  Pegah Varamini; Friederike M Mansfeld; Joanne T Blanchfield; Bruce D Wyse; Maree T Smith; Istvan Toth
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.